

Cover Story
By Alexandria Carolan and Paul Goldberg
Budget increases in 2020 enabled NCI to boost funding for research project grants, pushing the payline up by two percentage points from last year's level.
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for September 2020
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs













